Alpelisib

Alpelisib
Clinical data
Trade names	Piqray
Other names	BYL719
ATC code	L01XX65 (WHO) ;
Legal status
Legal status	US: ℞-only;
Identifiers
	IUPAC name (2S)-1-N-[4-Methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide;
CAS Number	1217486-61-7;
PubChem CID	56649450;
UNII	08W5N2C97Q;
CompTox Dashboard (EPA)	DTXSID70153355 ;
ECHA InfoCard	100.233.704
Chemical and physical data
Formula	C19H22F3N5O2S
Molar mass	441.47 g·mol−1
	InChI InChI=1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1; Key:STUWGJZDJHPWGZ-LBPRGKRZSA-N;

Alpelisib (INN; development code BYL719; brand name Piqray) is a medication sold by Novartis and used to treat certain types of breast cancer.^[1] It is used together with fulvestrant.^[1] It is taken by mouth.^[1]

Common side effects include high blood sugar, kidney problems, diarrhea, rash, low blood cells, liver problems, pancreatitis, vomiting, and hair loss.^[1] It is an alpha-specific PI3K inhibitor.^[1]^[2] It was approved for medical use in the United States in May of 2019.^[1]

References

^ ^a ^b ^c ^d ^e ^f "FDA approves first PI3K inhibitor for breast cancer". FDA. 24 May 2019. Retrieved 29 May 2019.
^ André, Fabrice; Ciruelos, Eva; Rubovszky, Gabor; Campone, Mario; Loibl, Sibylle; Rugo, Hope S.; Iwata, Hiroji; Conte, Pierfranco; Mayer, Ingrid A.; Kaufman, Bella; Yamashita, Toshinari; Lu, Yen-Shen; Inoue, Kenichi; Takahashi, Masato; Pápai, Zsuzsanna; Longin, Anne-Sophie; Mills, David; Wilke, Celine; Hirawat, Samit; Juric, Dejan; SOLAR-1 Study Group; the SOLAR-1 Study Group (2019). "Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer". New England Journal of Medicine. 380 (20): 1929–1940. doi:10.1056/NEJMoa1813904. PMID 31091374.{{cite journal}}: CS1 maint: numeric names: authors list (link)

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[FDA2019-1] ^ ^a ^b ^c ^d ^e ^f "FDA approves first PI3K inhibitor for breast cancer". FDA. 24 May 2019. Retrieved 29 May 2019.

[2] André, Fabrice; Ciruelos, Eva; Rubovszky, Gabor; Campone, Mario; Loibl, Sibylle; Rugo, Hope S.; Iwata, Hiroji; Conte, Pierfranco; Mayer, Ingrid A.; Kaufman, Bella; Yamashita, Toshinari; Lu, Yen-Shen; Inoue, Kenichi; Takahashi, Masato; Pápai, Zsuzsanna; Longin, Anne-Sophie; Mills, David; Wilke, Celine; Hirawat, Samit; Juric, Dejan; SOLAR-1 Study Group; the SOLAR-1 Study Group (2019). "Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer". New England Journal of Medicine. 380 (20): 1929–1940. doi:10.1056/NEJMoa1813904. PMID 31091374.{{cite journal}}: CS1 maint: numeric names: authors list (link)

[1]

[2]